Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Volatile Organic Compound (VOC)-Based Probe for Induced Volatolomics of Cancers.

Lange J, Eddhif B, Tarighi M, Garandeau T, Péraudeau E, Clarhaut J, Renoux B, Papot S, Poinot P.

Angew Chem Int Ed Engl. 2019 Sep 13. doi: 10.1002/anie.201906261. [Epub ahead of print]

PMID:
31518472
2.

The Lossen rearrangement from free hydroxamic acids.

Thomas M, Alsarraf J, Araji N, Tranoy-Opalinski I, Renoux B, Papot S.

Org Biomol Chem. 2019 Jun 5;17(22):5420-5427. doi: 10.1039/c9ob00789j. Review.

PMID:
31090777
3.

Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates.

Viricel W, Fournet G, Beaumel S, Perrial E, Papot S, Dumontet C, Joseph B.

Chem Sci. 2019 Mar 6;10(14):4048-4053. doi: 10.1039/c9sc00285e. eCollection 2019 Apr 14.

4.

Controlled Release of a Micelle Payload via Sequential Enzymatic and Bioorthogonal Reactions in Living Systems.

Porte K, Renoux B, Péraudeau E, Clarhaut J, Eddhif B, Poinot P, Gravel E, Doris E, Wijkhuisen A, Audisio D, Papot S, Taran F.

Angew Chem Int Ed Engl. 2019 May 6;58(19):6366-6370. doi: 10.1002/anie.201902137. Epub 2019 Mar 29.

PMID:
30856679
5.

A β-glucuronidase-responsive albumin-binding prodrug programmed for the double release of monomethyl auristatin E.

Renoux B, Fangous L, Hötten C, Péraudeau E, Eddhif B, Poinot P, Clarhaut J, Papot S.

Medchemcomm. 2018 Oct 26;9(12):2068-2071. doi: 10.1039/c8md00466h. eCollection 2018 Dec 1.

PMID:
30746064
6.

A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy.

Compain G, Oumata N, Clarhaut J, Péraudeau E, Renoux B, Galons H, Papot S.

Eur J Med Chem. 2018 Oct 5;158:1-6. doi: 10.1016/j.ejmech.2018.08.100. Epub 2018 Sep 3.

PMID:
30199702
7.

Reduction-rebridging strategy for the preparation of ADPN-based antibody-drug conjugates.

Koniev O, Dovgan I, Renoux B, Ehkirch A, Eberova J, Cianférani S, Kolodych S, Papot S, Wagner A.

Medchemcomm. 2018 Apr 20;9(5):827-830. doi: 10.1039/c8md00141c. eCollection 2018 May 1.

8.

TCA precipitation and ethanol/HCl single-step purification evaluation: One-dimensional gel electrophoresis, bradford assays, spectrofluorometry and Raman spectroscopy data on HSA, Rnase, lysozyme - Mascots and Skyline data.

Eddhif B, Guignard N, Batonneau Y, Clarhaut J, Papot S, Geffroy-Rodier C, Poinot P.

Data Brief. 2018 Feb 5;17:938-953. doi: 10.1016/j.dib.2018.01.095. eCollection 2018 Apr.

9.

Study of a novel agent for TCA precipitated proteins washing - comprehensive insights into the role of ethanol/HCl on molten globule state by multi-spectroscopic analyses.

Eddhif B, Lange J, Guignard N, Batonneau Y, Clarhaut J, Papot S, Geffroy-Rodier C, Poinot P.

J Proteomics. 2018 Feb 20;173:77-88. doi: 10.1016/j.jprot.2017.11.016. Epub 2017 Nov 27.

PMID:
29191748
10.

Editorial - Current advances in cancer research: Therapeutics, Targets, and Chemical Biology.

Galons H, Barraja P, Papot S.

Eur J Med Chem. 2017 Dec 15;142:1. doi: 10.1016/j.ejmech.2017.11.020. No abstract available.

PMID:
29153409
11.

Enhancing tumor response to targeted chemotherapy through up-regulation of folate receptor α expression induced by dexamethasone and valproic acid.

Péraudeau E, Cronier L, Monvoisin A, Poinot P, Mergault C, Guilhot F, Tranoy-Opalinski I, Renoux B, Papot S, Clarhaut J.

J Control Release. 2018 Jan 10;269:36-44. doi: 10.1016/j.jconrel.2017.11.011. Epub 2017 Nov 10.

PMID:
29129656
12.

Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.

Kolodych S, Michel C, Delacroix S, Koniev O, Ehkirch A, Eberova J, Cianférani S, Renoux B, Krezel W, Poinot P, Muller CD, Papot S, Wagner A.

Eur J Med Chem. 2017 Dec 15;142:376-382. doi: 10.1016/j.ejmech.2017.08.008. Epub 2017 Aug 4.

PMID:
28818506
13.

Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers.

Renoux B, Raes F, Legigan T, Péraudeau E, Eddhif B, Poinot P, Tranoy-Opalinski I, Alsarraf J, Koniev O, Kolodych S, Lerondel S, Le Pape A, Clarhaut J, Papot S.

Chem Sci. 2017 May 1;8(5):3427-3433. doi: 10.1039/c7sc00472a. Epub 2017 Mar 8.

14.

In situ targeted activation of an anticancer agent using ultrasound-triggered release of composite droplets.

Bezagu M, Clarhaut J, Renoux B, Monti F, Tanter M, Tabeling P, Cossy J, Couture O, Papot S, Arseniyadis S.

Eur J Med Chem. 2017 Dec 15;142:2-7. doi: 10.1016/j.ejmech.2017.03.057. Epub 2017 Mar 28.

PMID:
28416362
15.

Diminished oligomerization in the synthesis of new anti-angiogenic cyclic peptide using solution instead of solid-phase cyclization.

Rubio S, Clarhaut J, Péraudeau E, Vincenzi M, Soum C, Rossi F, Guillon J, Papot S, Ronga L.

Biopolymers. 2016 May;106(3):368-75. doi: 10.1002/bip.22814.

PMID:
26832831
16.

A dendritic β-galactosidase-responsive folate-monomethylauristatin E conjugate.

Alsarraf J, Péraudeau E, Poinot P, Tranoy-Opalinski I, Clarhaut J, Renoux B, Papot S.

Chem Commun (Camb). 2015 Nov 11;51(87):15792-5. doi: 10.1039/c5cc05294g.

PMID:
26365722
17.

Erratum to: Surface functionalization by covalent immobilization of an innovative carvacrol derivative to avoid fungal biofilm formation.

Gharbi A, Legigan T, Humblot V, Papot S, Imbert C, Berjeaud JM.

AMB Express. 2015 Dec;5(1):141. doi: 10.1186/s13568-015-0141-4. Epub 2015 Aug 21. No abstract available.

18.

Surface functionalization by covalent immobilization of an innovative carvacrol derivative to avoid fungal biofilm formation.

Gharbi A, Legigan T, Humblot V, Papot S, Berjeaud JM.

AMB Express. 2015 Feb 5;5:9. doi: 10.1186/s13568-014-0091-2. eCollection 2015. Erratum in: AMB Express. 2015 Dec;5(1):141.

19.

A mechanically interlocked molecular system programmed for the delivery of an anticancer drug.

Barat R, Legigan T, Tranoy-Opalinski I, Renoux B, Péraudeau E, Clarhaut J, Poinot P, Fernandes AE, Aucagne V, Leigh DA, Papot S.

Chem Sci. 2015 Apr 1;6(4):2608-2613. doi: 10.1039/c5sc00648a. Epub 2015 Feb 25.

20.

Evaluation of cytotoxic properties of a cyclopamine glucuronide prodrug in rat glioblastoma cells and tumors.

Bensalma S, Chadeneau C, Legigan T, Renoux B, Gaillard A, de Boisvilliers M, Pinet-Charvet C, Papot S, Muller JM.

J Mol Neurosci. 2015 Jan;55(1):51-61. doi: 10.1007/s12031-014-0395-3. Epub 2014 Oct 4.

PMID:
25280457
21.

Selective release of a cyclopamine glucuronide prodrug toward stem-like cancer cell inhibition in glioblastoma.

Balbous A, Renoux B, Cortes U, Milin S, Guilloteau K, Legigan T, Rivet P, Boissonnade O, Martin S, Tripiana C, Wager M, Bensadoun RJ, Papot S, Karayan-Tapon L.

Mol Cancer Ther. 2014 Sep;13(9):2159-69. doi: 10.1158/1535-7163.MCT-13-1038. Epub 2014 Jul 22.

22.

β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update.

Tranoy-Opalinski I, Legigan T, Barat R, Clarhaut J, Thomas M, Renoux B, Papot S.

Eur J Med Chem. 2014 Mar 3;74:302-13. doi: 10.1016/j.ejmech.2013.12.045. Epub 2014 Jan 11.

PMID:
24480360
23.

An enzyme-responsive system programmed for the double release of bioactive molecules through an intracellular chemical amplification process.

Grinda M, Legigan T, Clarhaut J, Peraudeau E, Tranoy-Opalinski I, Renoux B, Thomas M, Guilhot F, Papot S.

Org Biomol Chem. 2013 Nov 7;11(41):7129-33. doi: 10.1039/c3ob41536h.

PMID:
24057011
24.

Oxidative decarboxylation of diclofenac by manganese oxide bed filter.

Huguet M, Deborde M, Papot S, Gallard H.

Water Res. 2013 Sep 15;47(14):5400-8. doi: 10.1016/j.watres.2013.06.016. Epub 2013 Jun 18.

PMID:
23850215
25.

Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.

Legigan T, Clarhaut J, Renoux B, Tranoy-Opalinski I, Monvoisin A, Jayle C, Alsarraf J, Thomas M, Papot S.

Eur J Med Chem. 2013 Sep;67:75-80. doi: 10.1016/j.ejmech.2013.06.037. Epub 2013 Jun 25.

PMID:
23845743
26.

A galactosidase-responsive doxorubicin-folate conjugate for selective targeting of acute myelogenous leukemia blasts.

Clarhaut J, Fraineau S, Guilhot J, Peraudeau E, Tranoy-Opalinski I, Thomas M, Renoux B, Randriamalala E, Bois P, Chatelier A, Monvoisin A, Cronier L, Papot S, Guilhot F.

Leuk Res. 2013 Aug;37(8):948-55. doi: 10.1016/j.leukres.2013.04.026. Epub 2013 May 28.

PMID:
23726264
27.

The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.

Legigan T, Clarhaut J, Tranoy-Opalinski I, Monvoisin A, Renoux B, Thomas M, Le Pape A, Lerondel S, Papot S.

Angew Chem Int Ed Engl. 2012 Nov 12;51(46):11606-10. doi: 10.1002/anie.201204935. Epub 2012 Sep 20.

PMID:
22996951
28.

NDMA formation by chloramination of ranitidine: kinetics and mechanism.

Roux JL, Gallard H, Croué JP, Papot S, Deborde M.

Environ Sci Technol. 2012 Oct 16;46(20):11095-103. doi: 10.1021/es3023094. Epub 2012 Sep 26.

PMID:
22967139
29.

Gas chromatography-mass spectrometry of hexafluoroacetone derivatives: First time utilization of a gaseous phase derivatizing agent for analysis of extraterrestrial amino acids.

Geffroy-Rodier C, Buch A, Sternberg R, Papot S.

J Chromatogr A. 2012 Jul 6;1245:158-66. doi: 10.1016/j.chroma.2012.04.062. Epub 2012 May 12.

PMID:
22633064
30.

Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin.

Legigan T, Clarhaut J, Renoux B, Tranoy-Opalinski I, Monvoisin A, Berjeaud JM, Guilhot F, Papot S.

J Med Chem. 2012 May 10;55(9):4516-20. doi: 10.1021/jm300348r. Epub 2012 Apr 30.

PMID:
22515366
31.

Second generation specific-enzyme-activated rotaxane propeptides.

Fernandes A, Viterisi A, Aucagne V, Leigh DA, Papot S.

Chem Commun (Camb). 2012 Feb 18;48(15):2083-5. doi: 10.1039/c2cc17458h. Epub 2012 Jan 6.

PMID:
22227715
32.

A new cyclopamine glucuronide prodrug with improved kinetics of drug release.

Renoux B, Legigan T, Bensalma S, Chadéneau C, Muller JM, Papot S.

Org Biomol Chem. 2011 Dec 21;9(24):8459-64. doi: 10.1039/c1ob06081c. Epub 2011 Oct 31.

PMID:
22042246
33.

A heterodimeric glucuronide prodrug for cancer tritherapy: the double role of the chemical amplifier.

Grinda M, Clarhaut J, Tranoy-Opalinski I, Renoux B, Monvoisin A, Cronier L, Papot S.

ChemMedChem. 2011 Dec 9;6(12):2137-41. doi: 10.1002/cmdc.201100355. Epub 2011 Aug 3. No abstract available.

PMID:
21815268
34.

A galactosidase-responsive "trojan horse" for the selective targeting of folate receptor-positive tumor cells.

Thomas M, Clarhaut J, Strale PO, Tranoy-Opalinski I, Roche J, Papot S.

ChemMedChem. 2011 Jun 6;6(6):1006-10. doi: 10.1002/cmdc.201100114. Epub 2011 Mar 25. No abstract available.

PMID:
21442760
35.

Study of a cyclopamine glucuronide prodrug for the selective chemotherapy of glioblastoma.

Hamon F, Renoux B, Chadéneau C, Muller JM, Papot S.

Eur J Med Chem. 2010 Apr;45(4):1678-82. doi: 10.1016/j.ejmech.2009.12.067. Epub 2010 Jan 13.

PMID:
20116904
36.

Rotaxane-based propeptides: protection and enzymatic release of a bioactive pentapeptide.

Fernandes A, Viterisi A, Coutrot F, Potok S, Leigh DA, Aucagne V, Papot S.

Angew Chem Int Ed Engl. 2009;48(35):6443-7. doi: 10.1002/anie.200903215. No abstract available.

PMID:
19637268
37.

Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy.

Thomas M, Clarhaut J, Tranoy-Opalinski I, Gesson JP, Roche J, Papot S.

Bioorg Med Chem. 2008 Sep 1;16(17):8109-16. doi: 10.1016/j.bmc.2008.07.048. Epub 2008 Jul 23.

PMID:
18692397
38.

Design of self-immolative linkers for tumour-activated prodrug therapy.

Tranoy-Opalinski I, Fernandes A, Thomas M, Gesson JP, Papot S.

Anticancer Agents Med Chem. 2008 Aug;8(6):618-37. Review.

PMID:
18690826
39.

First O-glycosylation of hydroxamic acids.

Thomas M, Gesson JP, Papot S.

J Org Chem. 2007 May 25;72(11):4262-4. Epub 2007 Apr 28.

PMID:
17465568
40.

Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) beta-glucuronide and beta-galactoside for application in selective prodrug chemotherapy.

Thomas M, Rivault F, Tranoy-Opalinski I, Roche J, Gesson JP, Papot S.

Bioorg Med Chem Lett. 2007 Feb 15;17(4):983-6. Epub 2006 Nov 17.

PMID:
17157009
41.

Design of selectively activated anticancer prodrugs: elimination and cyclization strategies.

Papot S, Tranoy I, Tillequin F, Florent JC, Gesson JP.

Curr Med Chem Anticancer Agents. 2002 Mar;2(2):155-85. Review.

PMID:
12678742
42.

Aggressive behavior induced by the steroid sulfatase inhibitor COUMATE and by DHEAS in CBA/H mice.

Nicolas LB, Pinoteau W, Papot S, Routier S, Guillaumet G, Mortaud S.

Brain Res. 2001 Dec 20;922(2):216-22.

PMID:
11743952
43.

Synthesis of indomethacin analogues for evaluation as modulators of MRP activity.

Maguire AR, Plunkett SJ, Papot S, Clynes M, O'Connor R, Touhey S.

Bioorg Med Chem. 2001 Mar;9(3):745-62.

PMID:
11310610
44.

Synthesis and cytotoxic activity of a glucuronylated prodrug of nornitrogen mustard.

Papot S, Combaud D, Bosslet K, Gerken M, Czech J, Gesson JP.

Bioorg Med Chem Lett. 2000 Aug 21;10(16):1835-7.

PMID:
10969980
45.

A new spacer group derived from arylmalonaldehydes for glucuronylated prodrugs.

Papot S, Combaud D, Gesson JP.

Bioorg Med Chem Lett. 1998 Sep 22;8(18):2545-8.

PMID:
9873577

Supplemental Content

Support Center